Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIKAMIC hydroxycarbamide for albuminuria in adults with sickle cell disease
PACTR202103526168929Phase 2Not yet recruiting
- Sponsor
- ADDMEDICA
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Siklos with Placebo (2 arms). Primary endpoint: Albuminuria response at 6 months. Planned start May 2021; status: not yet recruiting.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202103526168929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202103526168929.